Out-of-pocket costs are higher for cancer patients who have a higher stage of disease at diagnosis, data suggest.

If confirmed, our findings may provide a more precise clinical target for definitive trials of PA as a prostate cancer treatment as well as for PA promotion efforts in newly diagnosed prostate cancer ...

This study underscores the need for future prospective studies and interventions to address current and impending drug shortages among practices, and a thorough policy approach is necessary to address ...

Democratic-controlled congressional committees and left-leaning think tanks are significantly more likely than their Republican counterparts to reference research papers, a study suggests.

The FDA has accepted for priority review the resubmitted BLA for tabelecleucel to treat patients 2 years of age and older with EBV+ PTLD who have received at least 1 prior therapy.